Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-07-25 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, a foreign issuer. It provides detailed information about the FDA granting Priority Review for Enhertu for HER2-low metastatic breast cancer, including clinical trial data, regulatory status, and drug development updates. Form 6-K filings are periodic reports submitted by foreign private issuers to provide material information that is not covered in their annual reports (Form 20-F). This document is not an annual report, earnings release, or management discussion, but rather a regulatory filing providing material news and updates. It is not a report publication announcement since it contains substantive information rather than just announcing a report's availability. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-07-25 English
Tezspire recommended for EU approval in asthma
Regulatory Filings Classification · 95% confidence The document is a press release issued via RNS (RNS Number : 5249T) on July 25, 2022, announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended marketing authorisation for AstraZeneca's drug Tezspire in the EU. This is a specific corporate announcement regarding regulatory progress, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is a formal regulatory update that doesn't fit the specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, although it is more specific than a typical RNS filing. However, given the options, RNS serves as the best fit for a non-standard, specific regulatory news release that isn't a core financial report or management change.
2022-07-25 English
Ultomiris recommended for EU approval for gMG
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 5248T' and is dated '25 July 2022'. It details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorisation of Ultomiris in the EU for generalized myasthenia gravis (gMG). This is a specific, time-sensitive announcement of a regulatory/clinical development milestone, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is a formal announcement disseminated via the RNS system (London Stock Exchange's news service), and it concerns a specific regulatory event (CHMP recommendation), it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update, although it is more specific than a generic RNS filing. Given the options, RNS is the most appropriate catch-all for non-standard, time-sensitive regulatory news releases that aren't covered by other specific codes like DIV, CAP, or ER. It is not a presentation (IP/AGM-R), a transcript (CT), or a management discussion (MDA).
2022-07-25 English
Enhertu granted Priority Review for HER2-low mBC
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (5247T) and the date stamp (25 July 2022 07:00 BST), indicating it is a regulatory news service announcement. The content details the FDA granting Priority Review for the drug Enhertu and provides extensive scientific and clinical trial updates (DESTINY-Breast04 results). This format—a brief announcement headline followed by detailed corporate and scientific commentary, often referencing regulatory actions (FDA, Priority Review, BTD)—is characteristic of a general regulatory filing or news release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement disseminated via RNS, and it is not a specific financial report, dividend notice, or management change, the most appropriate classification is the general Regulatory Filings category (RNS). The document length is substantial (17,774 chars), but its primary function is disseminating regulatory/clinical news via the RNS system.
2022-07-25 English
Amended group accounts made up to 2021-12-31
Regulatory Filings
2022-07-21 English
ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Enhertu in the EU for HER2-positive metastatic breast cancer, including clinical trial results, regulatory approvals, and financial considerations related to milestone payments. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory announcement providing material information about a product approval and related business updates. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they are periodic reports submitted by foreign private issuers to the SEC to disclose material information. The document length is substantial (15,000 characters), and it contains substantive content, but it is not a financial report per se. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-07-19 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.